Functional characterization of the ectopically expressed olfactory receptor 2AT4 in human myelogenous leukemia

Cell Death Discovery

Volumn 2, Issue 1, 2016, Pages

  Manteniotis, S ^a   Wojcik, S ^a   Brauhoff, P ^a   Mollmann M ^c   Petersen, L ^b   Göthert, Jr ^c   Schmiegel, W ^b   Duhrsen U ^c   Gisselmann, G ^a   Hatt, H ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84989287244     PISSN: None     EISSN: 20587716     Source Type: Journal    
DOI: 10.1038/cddiscovery.2015.70     Document Type: Article

References (48)

1. Burnett AK. New induction and postinduction strategies in acute myeloid leukemia. Curr Opin Hematol 2012; 19: 76–81.
2. Serve H, Krug U, Wagner R, Sauerland MC, Heinecke A, Brunnberg U et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol 2013; 31: 3110–3118.
3. Feldmesser E, Olender T, Khen M, Yanai I, Ophir R, Lancet D. Widespread ectopic expression of olfactory receptor genes. BMC Genom 2006; 7: 121.
4. Vanderhaeghen P, Schurmans S, Vassart G, Parmentier M. Molecular cloning and chromosomal mapping of olfactory receptor genes expressed in the male germ line: evidence for their wide distribution in the human genome. Biochem Biophys Res Commun 1997; 237: 283–287.
5. Flegel C, Manteniotis S, Osthold S, Hatt H, Gisselmann G. Expression profile of ectopic olfactory receptors determined by deep sequencing. PLoS One 2013; 8: e55368.
6. Neuhaus EM, Zhang W, Gelis L, Deng Y, Noldus J, Hatt H. Activation of an olfactory receptor inhibits proliferation of prostate cancer cells. J Biol Chem 2009; 284: 16218–16225.
7. Spehr M, Gisselmann G, Poplawski A, Riffell JA, Wetzel CH, Zimmer RK et al. Identification of a testicular odorant receptor mediating human sperm chemotaxis. Science 2003; 299: 2054–2058.
8. Weng J, Wang J, Hu X, Wang F, Ittmann M, Liu M. PSGR2, a novel G-protein coupled receptor, is overexpressed in human prostate cancer. Int J Cancer 2006; 118: 1471–1480.
9. Maßberg D, Simon A, Häussinger D, Keitel V, Gisselmann G, Conrad H et al. Monoterpene (-)-citronellal affects hepatocarcinoma cell signaling via an olfactory receptor. Arch Biochem Biophys 2014; 566: 100–109.
10. Braun T, Voland P, Kunz L, Prinz C, Gratzl M. Enterochromaffin cells of the human gut: sensors for spices and odorants. Gastroenterology 2007; 132: 1890–1901.
11. Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975; 45: 321–334.
12. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–2417.
13. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004; 103: 4010–4022.
14. Busse D, Kudella P, Grüning N, Gisselmann G, Ständer S, Luger T et al. A synthetic sandalwood odorant induces wound-healing processes in human keratinocytes via the olfactory receptor OR2AT4. J Invest Dermatol 2014; 134: 2823–2832.
15. Williams CL, Phelps SH, Porter RA. Expression of Ca2+/calmodulin-dependent protein kinase types II and IV, and reduced DNA synthesis due to the Ca2+/calmodulin-dependent protein kinase inhibitor KN-62 (1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenyl piperazine) in small cell lung carcinoma. Biochem Pharmacol 1996; 51: 707–715.
16. Ci W, Li W, Ke Y, Qian Z, Shen X. Intracellular Ca(2+) regulates the cellular iron uptake in K562 cells. Cell Calcium 2003; 33: 257–266.
17. Sasaki D, Kosunago S, Mikami T, Matsumoto T, Suzuki M. Growth-inhibition by hemin in K562 human leukemic cells is related to hemoglobin-producing activity. Biol Pharm Bull 1994; 17: 586–590.
18. Paz-Elizur T, Sevilya Z, Leitner-Dagan Y, Elinger D, Roisman LC, Livneh Z. DNA repair of oxidative DNA damage in human carcinogenesis: potential application for cancer risk assessment and prevention. Cancer Lett 2008; 266: 60–72.
19. Jaganathan SK, Mazumdar A, Mondhe D, Mandal M. Apoptotic effect of eugenol in human colon cancer cell lines. Cell Biol Int 2011; 35: 607–615.
20. Jaganathan SK, Supriyanto E. Antiproliferative and molecular mechanism of eugenol-induced apoptosis in cancer cells. Molecules 2012; 17: 6290–6304.
21. Sylvestre M, Legault J, Dufour D, Pichette A. Chemical composition and anticancer activity of leaf essential oil of Myrica gale L. Phytomedicine 2005; 12: 299–304.
22. Cragg GM, Newman DJ, Weiss RB. Coral reefs, forests, and thermal vents: the worldwide exploration of nature for novel antitumor agents. Semin Oncol 1997; 24: 156–163.
23. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007; 70: 461–477.
24. Zhang H, Tan S, Wang J, Chen S, Quan J, Xian J et al. Musashi2 modulates K562 leukemic cell proliferation and apoptosis involving the MAPK pathway. Exp Cell Res 2014; 320: 119–127.
25. Sweeney G, Somwar R, Ramlal T, Volchuk A, Ueyama A, Klip A. An inhibitor of p38 mitogen-activated protein kinase prevents insulin-stimulated glucose transport but not glucose transporter translocation in 3T3-L1 adipocytes and L6 myotubes. J Biol Chem 1999; 274: 10071–10078.
26. Heidenreich KA, Kummer JL. Inhibition of p38 mitogen-activated protein kinase by insulin in cultured fetal neurons. J Biol Chem 1996; 271: 9891–9894.
27. Dorsey JF, Cunnick JM, Mane SM, Wu J. Regulation of the Erk2-Elk1 signaling pathway and megakaryocytic differentiation of Bcr-Abl(+) K562 leukemic cells by Gab2. Blood 2002; 99: 1388–1397.
28. Persons DL, Yazlovitskaya EM, Cui W, Pelling JC. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin Cancer Res 1999; 5: 1007–1014.
29. Cummings BS, Schnellmann RG. Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. J Pharmacol Exp Ther 2002; 302: 8–17.
30. Li DW, Liu J, Mao Y, Xiang H, Wang J, Ma WY et al. Calcium-activated RAF/MEK/ERK signaling pathway mediates p53-dependent apoptosis and is abrogated by alpha B-crystallin through inhibition of RAS activation. Mol Biol Cell 2005; 16: 4437–4453.
31. Wang CL, Ng TB, Cao XH, Jiang Y, Liu ZK, Wen TY et al. CLP induces apoptosis in human leukemia K562 cells through Ca(2+) regulating extracellular-related protein kinase ERK activation. Cancer Lett 2009; 276: 221–227.
32. Kang CD, Yoo SD, Hwang BW, Kim KW, Kim CM, Kim SH et al. The inhibition of ERK/MAPK not the activation of JNK/SAPK is primarily required to induce apoptosis in chronic myelogenous leukemic K562 cells. Leuk Res 2000; 24: 527–534.
33. Stefanelli C, Tantini B, Fattori M, Stanic’ I, Pignatti C, Clo C et al. Caspase activation in etoposide-treated fibroblasts is correlated to ERK phosphorylation and both events are blocked by polyamine depletion. FEBS Lett 2002; 527: 223–228.
34. Tang D, Wu D, Hirao A, Lahti JM, Liu L, Mazza B et al. ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J Biol Chem 2002; 277: 12710–12717.
35. Lee E, Kang Y, Kim J, Lee HT, Cho S. Modulation of apoptosis in HaCaT keratinocytes via differential regulation of ERK signaling pathway by flavonoids. J Biol Chem 2005; 280: 31498–31507.
36. Alexia C, Fallot G, Lasfer M, Schweizer-Groyer G, Groyer A. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem Pharmacol 2004; 68: 1003–1015.
37. Fernández C, Ramos AM, Sancho P, Amrán D, Blas E de, Aller P. 12-O-tetradecanoylphorbol-13-acetate may both potentiate and decrease the generation of apoptosis by the antileukemic agent arsenic trioxide in human promonocytic cells. Regulation by extracellular signal-regulated protein kinases and glutathione. J Biol Chem 2004; 279: 3877–3884.
38. Lee E, Kim J, Kang Y, Ahn JY, Kim JH, Kim BW et al. Interplay between PI3K/Akt and MAPK signaling pathways in DNA-damaging drug-induced apoptosis. Biochim Biophys Acta 2006; 1763: 958–968.
39. Liu J, Mao W, Ding B, Liang C. ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes. Am J Physiol Heart Circ Physiol 2008; 295: H1956–H1965.
40. Lee Y, Soh J, Jeoung D, Cho CK, Jhon GJ, Lee SJ et al. PKC epsilon -mediated ERK1/2 activation involved in radiation-induced cell death in NIH3T3 cells. Biochim Biophys Acta 2003; 1593: 219–229.
41. Wang X, Martindale JL, Holbrook NJ. Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem 2000; 275: 39435–39443.
42. Woessmann W, Mivechi NF. Role of ERK activation in growth and erythroid differentiation of K562 cells. Exp Cell Res 2001; 264: 193–200.
43. Woessmann W, Zwanzger D, Borkhardt A. ERK signaling pathway is differentially involved in erythroid differentiation of K562 cells depending on time and the inducing agent. Cell Biol Int 2004; 28: 403–410.
44. Wang CL, Ng TB, Yuan F, Liu ZK, Liu F. Induction of apoptosis in human leukemia K562 cells by cyclic lipopeptide from Bacillus subtilis natto T-2. Peptides 2007; 28: 1344–1350.
45. Sawyers CL. Molecular consequences of the BCR-ABL translocation in chronic myelogenous leukemia. Leuk Lymphoma 1993; 11 (Suppl 2): 101–103.
46. Witt O, Sand K, Pekrun A. Butyrate-induced erythroid differentiation of human K562 leukemia cells involves inhibition of ERK and activation of p38 MAP kinase pathways. Blood 2000; 95: 2391–2396.
47. Huo X, Zhang J. Annexin1 regulates the erythroid differentiation through ERK signaling pathway. Biochem Biophys Res Commun 2005; 331: 1346–1352.
48. Palme D, Misovic M, Schmid E, Klumpp D, Salih HR, Rudner J et al. Kv3.4 potassium channel-mediated electrosignaling controls cell cycle and survival of irradiated leukemia cells. Pflugers Arch 2013; 465: 1209–1221.